Berlin, Germany – Epigenomics AG (ISIN: DE000A1K0516) announces that BioChain and certain of its shareholders will invest US$ 1.3 million (EUR 0.94 million) into the Company by subscribing 217,935 newly issued shares. This investment follows the signing of an agreement regarding a broad strategic collaboration of both companies announced today. Executive Board and Supervisory Board of Epigenomics today approved the increase of the share capital of the company from authorized capital against contribution in cash. The issue price has been set at EUR 4.32 per share. This constitutes a 5% discount to the two-day XETRA closing price average prior to the announcement. After registration of the capital increase, the subscribed capital of Epigenomics AG will increase from currently EUR 12,118,192 to EUR 12,336,127.
Epigenomics AG intends to use the net proceeds from the offering to finance its current operations and to strengthen the distribution capabilities, especially for its lead product Epi proColon®, a blood-based test for the early detection of colorectal cancer.
– End of Ad hoc –
Contact Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Phone: +49 (0) 30 24345 386
Epigenomics’ legal disclaimers. This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomicsproduct based on this technology which may be sold at some future time in the U.S. have not been established.